Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6526 to 6540 of 8930 results

  1. Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (TA280)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  2. Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

    This guidance has been updated and replaced by NICE guideline NG219.

    Withdrawn guidance

  3. Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)

    This guidance has been updated and replaced by NICE technology appraisal guidance 504.

    Withdrawn guidance

  4. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)

    This guidance has been updated and replaced by NICE technology appraisal guidance 386.

    Withdrawn guidance

  5. Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)

    The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.

    Withdrawn guidance

  6. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Withdrawn guidance

  7. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (TA271)

    This guidance has been updated and replaced by NICE technology appraisal guidance 301.

    Withdrawn guidance

  8. Familial breast cancer (CG14)

    This guidance has been updated and replaced by NICE guideline CG41.

    Withdrawn guideline

  9. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (CG144)

    This guidance has been updated and replaced by NICE guideline NG158.

    Withdrawn guideline

  10. Asfotase alfa for treating paediatric-onset hypophosphatasia (HST6)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 23.

    Withdrawn guidance

  11. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (HST3)

    This guidance has been updated and replaced by NICE highly specialised technologies guidance 22.

    Withdrawn guidance

  12. Elosulfase alfa for treating mucopolysaccharidosis type IVa (HST2)

    This guidance has been updated and replaced by NICE’s highly specialised technologies guidance on elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19).

    Withdrawn guidance

  13. Antimicrobial prescribing: cefiderocol (ES31)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn advice

  14. Parkinson's disease with motor fluctuations: safinamide (ES6)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice

  15. Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

    This evidence summary has been updated and replaced by NICE guideline NG71.

    Withdrawn advice